FARMACOS ANTIANGINOSOS PDF

16 out. FARMACOLOGIA CARDIOVASCULAR GRUPO 5. CASO CLÍNICO EXAME FÍSICO No momento da consulta, o exame físico não apresentava. Thank You! Farmacos Antianginosos e hipotensores. Una de las patologías y molestias mas frecuentes de la cardiopatía isquemica. MEDICAMENTOS CARDIOVASCULARES. Antianginosos. ATENOLOL. Comprimido 50 mg. (; ). Comprimido mg.

Author: Mezigul Dakus
Country: Iran
Language: English (Spanish)
Genre: Relationship
Published (Last): 9 January 2018
Pages: 378
PDF File Size: 6.11 Mb
ePub File Size: 11.16 Mb
ISBN: 791-2-19414-632-6
Downloads: 95844
Price: Free* [*Free Regsitration Required]
Uploader: Yokazahn

Prescription patterns for antilipidemic drugs in a group of Colombian patients. Existe subempleo de antianginosos y ASA y sobreempleo de antiinflamatorios y antiulcerosos. La dislipidemia es un factor de riesgo primario para desarrollar enfermedad coronaria y accidentes cerebrovasculares, causas frecuentes de morbilidad y mortalidad en Colombia y el mundo.

To determine patterns in antilipidemic drug prescriptions among a group of patients covered by the General Social Security System Sistema General de Seguridad Social in Colombia. A descriptive, observational study was conducted of 41 hyperlipidemics of both sexes, who were over 20 years of age, undergoing treatment from at least April to Juneand were residents of one of 19 cities in Colombia.

Nitroglicerina (fármaco) – Wikipédia, a enciclopédia livre

A database was created fafmacos track prescription data collected by the pharmaceutical company that dispenses medications to the patients. The mean age was Of the total number of patients, Prescriptions were ranked as follows: Comedications most frequently prescribed were: Antianginals and ASA were being underused, while antiinflamatories and antiulcer drugs were being overused.

  DREPTURILE SI OBLIGATIILE PACIENTILOR PDF

Dyslipidemia is a primary risk factor for developing coronary heart disease and stroke, frequent causes of morbidity and mortality in Colombia and the world. All of the antilipidemics are being antianbinosos at lower-than-recommended dosage levels. Clearly there is a need for creating educational strategies to address these prescribing habits and for exploring clinical results of the pharmaceuticals studied. Dyslipidemia; hyperlipidemia; hypertriglyceridemia; drug therapy, lipid; drugs with prescription; Colombia.

Estas investigaciones contribuyen al uso racional de medicamentos. Asimismo, disponen de bases de datos pertinentes y confiables.

FARMACOLOGIA CARDIOVASCULAR by Natanye Matchil on Prezi

Las diferencias halladas entre los pacientes tratados con monoterapia versus aquellos que reciben politerapia, se farmacso explicar porque existen pocas opciones de medicamentos y algunas asociaciones revisten riesgo. Vigilancia de los factores de riesgo para enfermedades no transmisibles: Cardiovascular disease and lipids.

Issues and evidence for the management of dyslipidaemia in primary care. Eur J Gen Pract.

Nitroglicerina (fármaco)

Acceso el 10 febrero Factores de riesgo para enfermedades cardiovasculares. Recommendations for the management of dyslipidemia and prevention of cardiovascular disease: Distribution and correlates of lipids and lipoproteins in elderly Japanese-American men. Arterioscler Thromb Vasc Biol.

  COMUNICACION ESCRITA HECTOR PEREZ GRAJALES PDF

Strategies for optimizing treatment outcomes. J Manag Care Pharm. Primatesta P, Poulter RN. Lipid concentrations and the use of lipid lowering drugs: Cholesterol control, medication adherence and illness cognition. Br J Health Psychol. Sanal S, Aronow WS. Effect of an educational program on the prevalence of use of anti platelet drugs, beta blockers, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers prescribed during hospitalization and at hospital discharge in patients with coronary artery disease.

Management of hyperlipidaemia after coronary revascularisation: Consejo Nacional de Seguridad Social en Salud. Acuerdo de Patrones de uso de antihipertensivos en 11 pacientes colombianos. Differences between clinical trial efficacy and real-world effectiveness.

Am J Manag Care. Effective use of combination lipid therapy. Update for primary healthcare providers: The use of a hospital laboratory cohort to estimate the prevalence of dyslipidemia in an adult Bra zilian antiangjnosos. Int J Clin Pract ; Manuscrito recibido el 19 de enero de ReadCube Visualizar o texto. Similares xntianginosos Google Citados no Google Scholar.